One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Alnylam Pharmaceuticals now clears that threshold, with a jump from 76 to 86 Tuesday.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains tend to have an 80 or better RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Alnylam Pharmaceuticals is working on a consolidation with a 304.39 entry. See if the stock can clear the breakout price in volume at least 40% above average.
The company showed 0% earnings growth last quarter. Revenue rose -33%. Keep an eye out for the company's next round of numbers on or around Feb. 6.
The company earns the No. 92 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
